COMMUNIQUÉS West-GlobeNewswire

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
12/05/2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection [...]
Vireo Growth Inc. Announces First Quarter 2026 Results
12/05/2026
Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions Moves to 4 th largest cannabis company on a pro forma basis by revenue Closed the Schwazze acquisition [...]
Immatics Announces First Quarter 2026 Financial Results and Business Update
12/05/2026
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027 Multiple key clinical data sets [...]
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team [...]
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
12/05/2026
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic engineering Findings [...]
CorVel Corporation to Host Live Earnings Release Webcast
12/05/2026
FORT WORTH, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a leading provider of innovative risk management solutions, is pleased to announce that it will host a live webcast to discuss its [...]
ProQR Announces First Quarter 2026 Operating and Financial Results
12/05/2026
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the [...]
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class [...]
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
12/05/2026
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 [...]
Harvard Bioscience Announces First Quarter 2026 Financial Results
12/05/2026
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE [...]
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
12/05/2026
Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase [...]
Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases
12/05/2026
- Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a single AAV vector - Two poster presentations describe methods that support accelerated [...]
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
12/05/2026
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogens Infex to present results from Phase IIa trial for first-in-class anti-virulence therapy [...]
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
12/05/2026
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced [...]
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
12/05/2026
Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepted to FDA’s Rare [...]
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
12/05/2026
Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients First clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter [...]
American Shared Hospital Services Announces First Quarter 2026 Financial Results Conference Call
12/05/2026
Call Scheduled for May 14th at 12:00 PM ET SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
12/05/2026
Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior Vice President of Commercial and Vice President of Sales, reuniting the team behind the launch of Ohtuvayre®, one of the [...]
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
12/05/2026
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth 1 in constant currencies. Strong quarter in Chronic Care and Interventional [...]

Pages